Search clinical trials for: Comparator Protease Inhibitor (CPI)

Total 6317 results

Bristol-Myers Squibb

Completed

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Deep Vein Thrombosis | Pulmonary Embolism

Mexico
Seoul National University Hospital
Korean Society of Hematology Thrombosis Working Party

Completed

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Recurrence | Bleeding | Cancer-associated Thrombosis | Rivaroxaban

Korea, Republic of
London Health Sciences Centre

Completed

Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)

Central Venous Catheter Thrombosis | Neoplasm

Canada
Bristol-Myers Squibb

Completed

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Venous Thromboembolism

Korea, Republic of
Bristol-Myers Squibb

Completed

Safety Study of Apixaban in Recent Acute Coronary Syndrome

Acute Coronary Syndrome (ACS)

Canada, Italy, Poland, Sweden, United States, Spain, Austria, Denmark, France, Belgium, Israel, Germany, Russian Federation, United Kingdom
Astellas Pharma Inc

Completed

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

Venous Thromboembolism

Japan
Aswan University Hospital

Completed

Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage

Cesarean Section Complications

Egypt
National Institutes of Health Clinical Center (CC)

Completed

Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers

Healthy Volunteers

United States
Sichuan Provincial People's Hospital

Recruiting

Treatment of ARDS With Sivelestat Sodium (TOAWSS)

Acute Respiratory Distress Syndrome

China
The Medicines Company

Withdrawn

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Heparin-Induced Thrombocytopenia | Heparin-induced Thrombocytopenia and Thrombosis Syndrome

United States
Prof. Stavros Konstantinides, MD
European Georges Pompidou Hospital

Terminated

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. (PEITHO-2)

Pulmonary Embolism

Germany
The Medicines Company

Completed

Bivalirudin as a Procedural Anticoagulant in Pediatrics

Cardiology
The Medicines Company

Completed

Study Of Angiomax In Infants Under Six Months With Thrombosis

Thrombosis

United States
Kamada, Ltd.

Completed

Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Cystic Fibrosis

Israel
Irina Ermolaeva

Recruiting

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD (RE-ELECT)

Chronic Kidney Diseases | Atrial Fibrillation | T2DM (Type 2 Diabetes Mellitus)

Russian Federation
George Washington University

Completed

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study (ATHOS)

Septic Shock

United States
University of Illinois at Chicago
La Jolla Pharmaceutical Company

Completed

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

Shock | Kidney Transplant; Complications | Hypotension and Shock | Intraoperative Hypotension | Shock, Surgical | Postoperative Hypotension

United States
Alissa Gubeli
Spentys

Completed

Overnight and In-house 3D-printed Patient-specific Casts for Non-operative Treatment of Distal Radius Fractures (3D-cast)

Radius Fracture Distal

Switzerland
Boehringer Ingelheim

Completed

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Atrial Fibrillation

Japan
Boehringer Ingelheim

Completed

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Venous Thromboembolism
Boehringer Ingelheim

Completed

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Healthy

Belgium
Pfizer

Completed

Drug Interaction Study Between Bosutinib And Dabigatran

Healthy

United States
AstraZeneca

Terminated

Long Term Open Follow-up With H376/95 vs. Warfarin

Stroke Prevention in Patients With Atrial Fibrillation

Sweden, Norway, Poland, United Kingdom, Finland, Denmark, United States, Czech Republic, Belgium
Shanghai Tong Ren Hospital

Recruiting

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction (PERFECT-AMI)

Early PCSK9 Inhibitor on Ventricular Remodling

China
University Hospital Tuebingen

Terminated

Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion

Insulin Resistance | Hypercholesterolemia | Insulin Secretion

Germany
Assiut University

Not yet recruiting

Serum Cystatin C for Early Detection of Acute Kidney Injury After Primary Percutaneous Coronary Intervention

Acute Kidney Injury
The Affiliated Hospital Of Guizhou Medical University

Not yet recruiting

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

Healthy

United States
Sahlgrenska University Hospital, Sweden

Completed

Heart and Renal Failure in Hip Fracture Surgery

Renal Insufficiency | Hip Fractures | Hypotension | Heart Injuries

Sweden
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Hepatic Insufficiency
ViiV Healthcare
GlaxoSmithKline

Completed

48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection

Infection, Human Immunodeficiency Virus I

United States, Spain, Canada, Russian Federation, Romania, Belgium, South Africa
Azienda Ospedaliero, Universitaria Ospedali Riuniti

Recruiting

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

Intracardiac Thrombus

Italy
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk (SHORT RUN AF)

Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
Institute for Clinical and Experimental Medicine

Recruiting

DOT HeartMate 3 Study

LVAD (Left Ventricular Assist Device) Thrombosis

Czechia
Pfizer

Completed

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Non-valvular Atrial Fibrillation

Japan
Brigham and Women's Hospital

Completed

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Venous Thromboembolism

United States
University Hospital, Caen
University Hospital, Rouen

Completed

Apixaban in Subjects With Peritoneal Dialysis (ApiDP)

Peritoneal Dialysis | Chronic Renal Insufficiency

France
Veralox Therapeutics
Celerion

Completed

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Heparin-induced Thrombocytopenia

United States
Hyogo College of Medicine

Completed

Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial (ALVO)

Ischemic Stroke

Japan
Mayo Clinic
Bristol-Myers Squibb; Pfizer

Terminated

Calf Deep Vein Thrombosis Treatment Trial

Deep Vein Thrombosis

United States
Genuine Research Center, Egypt
Horus for Pharmaceutical Industries, Egypt

Completed

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

Healthy

Egypt
Bristol-Myers Squibb

Completed

Bioavailability of Apixaban Crushed Tablet

Thrombosis
Astellas Pharma Inc

Completed

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

Venous Thromboembolism

Japan
Encysive Pharmaceuticals
GlaxoSmithKline

Completed

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Thrombosis | Thrombocytopenia

United States
International Bio service

Not yet recruiting

Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Ono Pharmaceutical Co. Ltd

Completed

Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male Subjects

Healthy Volunteers

Japan
Daiichi Sankyo, Inc.

Completed

Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (ETNA-AF-EU)

Atrial Fibrillation

Spain, Italy, Germany, Switzerland, Portugal, Belgium, Austria, Ireland, Netherlands, United Kingdom
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

Atrial Fibrillation

Search clinical trials for: Comparator Protease Inhibitor (CPI)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations